Title:
STRENGTHENED RECEPTOR, AND IMMUNE CELL EXPRESSING STRENGTHENED RECEPTOR AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/046394
Kind Code:
A1
Abstract:
Provided are a TIGIT and OX40-based strengthened receptor (TIGIT/OX40) capable of increasing the activation level and survival time of immune cells, and an immune cell modified to express the strengthened receptor. Also provided is an immune cell modified to express two different strengthened receptors containing the strengthened receptor.
More Like This:
Inventors:
ZHAO JIE (CN)
GAO BIN (CN)
GU WEIYUE (CN)
GAO BIN (CN)
GU WEIYUE (CN)
Application Number:
PCT/CN2023/115934
Publication Date:
March 07, 2024
Filing Date:
August 30, 2023
Export Citation:
Assignee:
CHINEO MEDICAL TECH CO LTD (CN)
International Classes:
C07K19/00; A61K35/17; A61K39/395; A61P35/00; C12N5/10; C12N15/10
Domestic Patent References:
| WO2021142835A1 | 2021-07-22 |
Foreign References:
| CN111544585A | 2020-08-18 | |||
| CN110511912A | 2019-11-29 | |||
| CN111542595A | 2020-08-14 | |||
| CN110381983A | 2019-10-25 | |||
| US20150010567A1 | 2015-01-08 | |||
| CN111432828A | 2020-07-17 |
Other References:
OBAJDIN, J. ET AL.: "Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer", CLINICAL & EXPERIMENTAL IMMUNOLOGY, vol. 202, 16 June 2020 (2020-06-16), pages 11 - 27, XP071082542, DOI: 10.1111/cei.13478
GE, Z. H ET AL.: "TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer", FRONTIERS IN IMMUNOLOGY, vol. 12, no. 699895, 31 July 2021 (2021-07-31), pages 1 - 13, XP055973881, DOI: 10.3389/fimmu.2021.699895
GE, Z. H ET AL.: "TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer", FRONTIERS IN IMMUNOLOGY, vol. 12, no. 699895, 31 July 2021 (2021-07-31), pages 1 - 13, XP055973881, DOI: 10.3389/fimmu.2021.699895
Attorney, Agent or Firm:
IPFAITH PARTNERS (CN)
Download PDF: